Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
Total Valuation
Catalyst Pharma has a market cap or net worth of $2.99B. The enterprise value is $2.34B.
Market Cap$2.99B
Enterprise Value$2.34B
Share Statistics
Catalyst Pharma has 121,975,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding121,975,150
Owned by Insiders6.23%
Owned by Institutions16.60%
Financial Efficiency
Catalyst Pharma’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is 20.24%.
Return on Equity (ROE)0.23
Return on Assets (ROA)0.19
Return on Invested Capital (ROIC)20.24%
Return on Capital Employed (ROCE)0.27
Revenue Per Employee2.72M
Profits Per Employee905.46K
Employee Count181
Asset Turnover0.58
Inventory Turnover3.52
Valuation Ratios
The current PE Ratio of Catalyst Pharma is 15.08. Catalyst Pharma’s PEG ratio is 1.53.
PE Ratio15.08
PS Ratio0.00
PB Ratio3.85
Price to Fair Value3.40
Price to FCF11.91
Price to Operating Cash Flow11.68
PEG Ratio1.53
Income Statement
In the last 12 months, Catalyst Pharma had revenue of 491.73M and earned 163.89M in profits. Earnings per share was 1.38.
Revenue491.73M
Gross Profit422.89M
Operating Income195.12M
Pretax Income216.26M
Net Income163.89M
EBITDA232.90M
Earnings Per Share (EPS)1.38
Cash Flow
In the last 12 months, operating cash flow was 239.81M and capital expenditures -556.00K, giving a free cash flow of 239.25M billion.
Operating Cash Flow239.81M
Free Cash Flow239.25M
Free Cash Flow per Share1.96
Dividends & Yields
Catalyst Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.96
52-Week Price Change56.42%
50-Day Moving Average23.58
200-Day Moving Average21.90
Relative Strength Index (RSI)59.17
Average Volume (3m)987.33K
Important Dates
Catalyst Pharma upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 7, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Catalyst Pharma as a current ratio of 5.17, with Debt / Equity ratio of 0.44%
Current Ratio5.17
Quick Ratio5.01
Debt to Market Cap0.00
Net Debt to EBITDA-2.21
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Catalyst Pharma has paid 52.37M in taxes.
Income Tax52.37M
Effective Tax Rate0.24
Enterprise Valuation
Catalyst Pharma EV to EBITDA ratio is 8.41, with an EV/FCF ratio of 8.18.
EV to Sales3.98
EV to EBITDA8.41
EV to Free Cash Flow8.18
EV to Operating Cash Flow8.16
Balance Sheet
Catalyst Pharma has $517.55M in cash and marketable securities with $3.19M in debt, giving a net cash position of -$514.37M billion.
Cash & Marketable Securities$517.55M
Total Debt$3.19M
Net Cash-$514.37M
Net Cash Per Share-$4.22
Tangible Book Value Per Share$4.82
Margins
Gross margin is 84.10%, with operating margin of 39.68%, and net profit margin of 33.33%.
Gross Margin84.10%
Operating Margin39.68%
Pretax Margin43.98%
Net Profit Margin33.33%
EBITDA Margin47.36%
EBIT Margin39.68%
Analyst Forecast
The average price target for Catalyst Pharma is $33.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$33.00
Price Target Upside32.85% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast29.97%
EPS Growth Forecast178.11%